EGRX - Eagle Pharmaceuticals, Inc.
| Previous Close | 53.85 |
| Open | 54.79 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 54.10 - 55.50 |
| 52 Week Range | 36.03 - 83.79 |
| Volume | 88,991 |
| Avg. Volume | 169,620 |
| Market Cap | 745.554M |
| Beta (3Y Monthly) | 1.86 |
| PE Ratio (TTM) | 21.37 |
| EPS (TTM) | 2.55 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.33 |
- MarketWatch•21 days ago
Park Service diverts $2.5 million in fees to pay for Trump’s July 4th celebration | Beto O’Rourke says he’s unaware of his fundraising numbers
The Washington Post reports the National Park Service is diverting nearly $2.5 million in entrance and recreation fees primarily intended to improve parks across the country to cover costs associated with President Donald Trump’s Independence Day celebration on the Mall.
- Markit•last month
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high and has been increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for EGRX with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting EGRX. Sentiment has worsened and traders added to their bearish short positions on June 6. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding EGRX are favorable, with net inflows of $1.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.•2 months ago
Here's Why I Think Eagle Pharmaceuticals (NASDAQ:EGRX) Might Deserve Your Attention Today
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
- Business Wire•2 months ago
Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT
Q1 2019 Eagle Pharmaceuticals Inc Earnings Call
- Business Wire•2 months ago
Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
- Insider Monkey•2 months ago
Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc (EGRX)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
- MoneyShow•3 months ago
Can Eagle Pharma Fly through its Oncology Trials
Since we began covering Eagle Pharmaceuticals (EGRX) in January 2018, the company has made progress in its portfolio of critical care and oncology treatments, but its share price has not reflected those gains. We believe there is upside potential making the stock worth reconsidering.
Motley Fool•3 months agoEagle Pharmaceuticals Inc (EGRX) Q1 2019 Earnings Call Transcript
EGRX earnings call for the period ending March 31, 2019.
- Zacks•3 months ago
Eagle Pharmaceuticals (EGRX) Beats Q1 Earnings and Revenue Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 77.19% and 12.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.•3 months ago
Did You Miss Eagle Pharmaceuticals's (NASDAQ:EGRX) Whopping 457% Share Price Gain?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Buying shares in the best businesses can build meaningful wealth for you and your family. While...
- Associated Press•3 months ago
Eagle Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the Woodcliff Lake, New Jersey-based company said it had net income of 62 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to $1.01 per share. The ...
- Business Wire•3 months ago
Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results
-- Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of $1.05 per basic and $1.01 per diluted share --
- Business Wire•3 months ago
Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced positive results of its study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium) secondary to nerve agent (NA) exposure, conducted with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development. The study results show a p-value of 0.04 or less compared to the control group in six critical areas of the brain.
- Zacks•3 months ago
Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•3 months ago
Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2019 first quarter financial results on Tuesday, May 7, 2019, before the market opens.
- Zacks•3 months ago
New Strong Sell Stocks for April 22nd
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- Business Wire•3 months ago
CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code, or J-code (J9036), for BELRAPZO™ (bendamustine 500mL hydrochloride injection). Eagle’s bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019.
- Business Wire•3 months ago
Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today announced that it has expanded its existing BENDEKA™ (bendamustine hydrochloride) licensing agreement with Teva Pharmaceuticals International GmbH (“Teva”). Under the terms of the revised licensing agreement, beginning on October 1, 2019, Eagle’s royalty payment will increase from 25% to 30% of BENDEKA net U.S. sales, provided that BENDEKA’s orphan drug exclusivity has not been rescinded, withdrawn or waived by such date.
- Simply Wall St.•4 months ago
Don't Sell Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Before You Read This
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll s...
